Follow
Dominik Andreas Barth
Dominik Andreas Barth
Verified email at medunigraz.at
Title
Cited by
Cited by
Year
C-reactive protein (CRP) levels in immune checkpoint inhibitor response and progression in advanced non-small cell lung cancer: a bi-center study
JM Riedl, DA Barth, WM Brueckl, G Zeitler, V Foris, S Mollnar, M Stotz, ...
Cancers 12 (8), 2319, 2020
622020
Long-noncoding RNA (lncRNA) in the regulation of hypoxia-inducible factor (HIF) in cancer
DA Barth, F Prinz, J Teppan, K Jonas, C Klec, M Pichler
Non-coding RNA 6 (3), 27, 2020
422020
Non-coding RNAs and SARS-related coronaviruses
H Henzinger, DA Barth, C Klec, M Pichler
Viruses 12 (12), 1374, 2020
382020
Current concepts of non-coding RNAs in the pathogenesis of non-clear cell renal cell carcinoma
DA Barth, O Slaby, C Klec, J Juracek, R Drula, GA Calin, M Pichler
Cancers 11 (10), 1580, 2019
372019
Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis
JM Riedl, F Posch, L Horvath, A Gantschnigg, F Renneberg, ...
European Journal of Cancer 151, 3-13, 2021
362021
Involvement of long non-coding RNAs (lncRNAs) in tumor angiogenesis
J Teppan, DA Barth, F Prinz, K Jonas, M Pichler, C Klec
Non-coding RNA 6 (4), 42, 2020
342020
lncRNA and mechanisms of drug resistance in cancers of the genitourinary system
DA Barth, J Juracek, O Slaby, M Pichler, GA Calin
Cancers 12 (8), 2148, 2020
322020
Circulating non-coding RNAs in renal cell carcinoma—pathogenesis and potential implications as clinical biomarkers
DA Barth, R Drula, L Ott, L Fabris, O Slaby, GA Calin, M Pichler
Frontiers in Cell and Developmental Biology 8, 828, 2020
252020
Involvement of long non-coding RNAs in glucose metabolism in cancer
A Balihodzic, DA Barth, F Prinz, M Pichler
Cancers 13 (5), 977, 2021
232021
Evaluation of autoantibodies as predictors of treatment response and immune‐related adverse events during the treatment with immune checkpoint inhibitors: A prospective …
DA Barth, S Stanzer, J Spiegelberg, T Bauernhofer, G Absenger, F Posch, ...
Cancer Medicine 11 (16), 3074-3083, 2022
192022
Emerging role of non-coding RNAs in regulation of T-lymphocyte function
M Taheri, DA Barth, J Kargl, O Rezaei, S Ghafouri-Fard, M Pichler
Frontiers in Immunology 12, 756042, 2021
192021
External validation of the prognostic relevance of the advanced lung cancer inflammation index (ALI) in pancreatic cancer patients
DA Barth, C Brenner, JM Riedl, F Prinz, EV Klocker, K Schlick, P Kornprat, ...
Cancer Medicine 9 (15), 5473-5479, 2020
192020
The AST/ALT ratio is an independent prognostic marker for disease-free survival in stage II and III colorectal carcinoma
L Scheipner, MA Smolle, D Barth, F Posch, M Stotz, M Pichler, H Stoeger, ...
Anticancer Research 41 (1), 429-436, 2021
182021
Long non-coding RNA PANTR1 is associated with poor prognosis and influences angiogenesis and apoptosis in clear-cell renal cell cancer
M Seles, GC Hutterer, J Foßelteder, M Svoboda, M Resel, DA Barth, ...
Cancers 12 (5), 1200, 2020
152020
MicroRNAs as appropriate discriminators in non-specific alpha-fetoprotein (AFP) elevation in testicular germ cell tumor patients
AL Lembeck, P Puchas, G Hutterer, DA Barth, A Terbuch, T Bauernhofer, ...
Non-coding RNA 6 (1), 2, 2020
132020
The lipase/amylase ratio (LAR) in peripheral blood might represent a novel prognostic marker in patients with surgically resectable pancreatic cancer
M Stotz, DA Barth, JM Riedl, E Asamer, EV Klocker, P Kornprat, ...
Cancers 12 (7), 1798, 2020
112020
Decreased activity of circulating butyrylcholinesterase in blood is an independent prognostic marker in pancreatic cancer patients
EV Klocker, DA Barth, JM Riedl, F Prinz, J Szkandera, K Schlick, ...
Cancers 12 (5), 1154, 2020
112020
Patterns of thromboembolism in patients with advanced pancreatic cancer undergoing first-line chemotherapy with FOLFIRINOX or gemcitabine/nab-paclitaxel
JM Riedl, E Schwarzenbacher, F Moik, L Horvath, A Gantschnigg, ...
Thrombosis and Haemostasis 122 (04), 633-645, 2022
102022
Patterns of peripheral blood b-cell subtypes are associated with treatment response in patients treated with immune checkpoint inhibitors: A prospective longitudinal pan-cancer …
DA Barth, S Stanzer, JA Spiegelberg, T Bauernhofer, G Absenger, ...
Frontiers in immunology 13, 840207, 2022
92022
MiR-200c-3p modulates cisplatin resistance in biliary tract cancer by ZEB1-independent mechanisms
F Posch, F Prinz, A Balihodzic, C Mayr, T Kiesslich, C Klec, K Jonas, ...
Cancers 13 (16), 3996, 2021
82021
The system can't perform the operation now. Try again later.
Articles 1–20